ECSP21027262A - Agentes de ARNi para inhibir la expresión de 17beta-HSD tipo 13 (HSD17B13), composiciones de dichos agentes, y métodos de uso - Google Patents

Agentes de ARNi para inhibir la expresión de 17beta-HSD tipo 13 (HSD17B13), composiciones de dichos agentes, y métodos de uso

Info

Publication number
ECSP21027262A
ECSP21027262A ECSENADI202127262A ECDI202127262A ECSP21027262A EC SP21027262 A ECSP21027262 A EC SP21027262A EC SENADI202127262 A ECSENADI202127262 A EC SENADI202127262A EC DI202127262 A ECDI202127262 A EC DI202127262A EC SP21027262 A ECSP21027262 A EC SP21027262A
Authority
EC
Ecuador
Prior art keywords
hsd17b13
rnai agents
methods
agents
expression
Prior art date
Application number
ECSENADI202127262A
Other languages
English (en)
Spanish (es)
Inventor
Rui Zhu
Zhen Li
Shawn A Morales
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Publication of ECSP21027262A publication Critical patent/ECSP21027262A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/331—Universal or degenerate base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ECSENADI202127262A 2018-09-19 2021-04-19 Agentes de ARNi para inhibir la expresión de 17beta-HSD tipo 13 (HSD17B13), composiciones de dichos agentes, y métodos de uso ECSP21027262A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862733320P 2018-09-19 2018-09-19
US201862773707P 2018-11-30 2018-11-30
US201962890220P 2019-08-22 2019-08-22

Publications (1)

Publication Number Publication Date
ECSP21027262A true ECSP21027262A (es) 2021-05-31

Family

ID=69887755

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202127262A ECSP21027262A (es) 2018-09-19 2021-04-19 Agentes de ARNi para inhibir la expresión de 17beta-HSD tipo 13 (HSD17B13), composiciones de dichos agentes, y métodos de uso

Country Status (21)

Country Link
US (1) US12534728B2 (enExample)
EP (1) EP3852769A4 (enExample)
JP (3) JP7488254B2 (enExample)
KR (1) KR102769565B1 (enExample)
CN (2) CN122235140A (enExample)
AU (1) AU2019342117B9 (enExample)
BR (1) BR112021005137A2 (enExample)
CA (1) CA3109553A1 (enExample)
CL (1) CL2021000669A1 (enExample)
CO (1) CO2021003446A2 (enExample)
CR (1) CR20210186A (enExample)
EC (1) ECSP21027262A (enExample)
IL (1) IL281597B1 (enExample)
MX (1) MX2021003077A (enExample)
MY (1) MY209138A (enExample)
PE (1) PE20211212A1 (enExample)
PH (1) PH12021550423A1 (enExample)
SG (1) SG11202101698WA (enExample)
TW (1) TWI870358B (enExample)
UY (1) UY38382A (enExample)
WO (1) WO2020061177A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170056B1 (ar) * 2016-09-02 2021-08-17 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة
MY207352A (en) 2018-03-21 2025-02-21 Regeneron Pharma 17-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
US12534728B2 (en) * 2018-09-19 2026-01-27 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of 17beta-HSD type 13 (HSD17B13), compositions thereof, and methods of use
SG11202106378VA (en) * 2018-12-21 2021-07-29 Ionis Pharmaceuticals Inc Modulators of hsd17b13 expression
US20230279399A1 (en) * 2020-06-01 2023-09-07 Amgen Inc. Rnai constructs for inhibiting hsd17b13 expression and methods of use thereof
WO2022098748A1 (en) * 2020-11-06 2022-05-12 Inipharm, Inc. Uses for hsd17b13 inhibitors
EP4267739A1 (en) 2020-12-23 2023-11-01 Regeneron Pharmaceuticals, Inc. Treatment of liver diseases with cell death inducing dffa like effector b (cideb) inhibitors
EP4328310A4 (en) * 2021-04-22 2025-10-15 Tuojie Biotech Shanghai Co Ltd SIRNA TARGETING 17β-HYDROXYSTEROID DEHYDROGENASE TYPE 13 AND SIRNA CONJUGATE
CA3229569A1 (en) 2021-08-20 2023-02-23 Enanta Pharmaceuticals, Inc. 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof
CA3230382A1 (en) * 2021-09-08 2023-03-16 Aligos Therapeutics, Inc. Modified short interfering nucleic acid (sina) molecules and uses thereof
CN118251492A (zh) * 2021-11-18 2024-06-25 诺华股份有限公司 用于治疗夏科-马里-图思病的靶向pmp22的化合物
JP2024545602A (ja) * 2021-11-19 2024-12-10 ウェイブ ライフ サイエンシズ リミテッド Ｈｓｄ１７ｂ１３関連二本鎖オリゴヌクレオチド組成物及びそれに関連する方法
TW202340466A (zh) * 2021-12-16 2023-10-16 大陸商上海拓界生物醫藥科技有限公司 一種ｄｓｒｎａ、其製備方法及應用
EP4453257A2 (en) 2021-12-20 2024-10-30 Regeneron Pharmaceuticals, Inc. Methods of identifying and evaluating liver inflammation and liver fibrosis in a subject by determining a stratified score based on gene expression
CN118541487A (zh) * 2022-01-20 2024-08-23 上海拓界生物医药科技有限公司 一种dsRNA、其应用及制备方法
CN119789859A (zh) 2022-04-08 2025-04-08 箭头药业股份有限公司 非酒精性脂肪肝病的治疗
IL315794A (en) * 2022-04-28 2024-11-01 Enanta Pharm Inc Pyrimidine containing 17-beta-hydrosteroid dehydrogenase type 13 inhibitors
WO2023208109A1 (zh) * 2022-04-29 2023-11-02 北京福元医药股份有限公司 用于抑制HSD17B13表达的siRNA、其缀合物和药物组合物及其用途
TW202400791A (zh) * 2022-05-06 2024-01-01 大陸商蘇州瑞博生物技術股份有限公司 一種核酸、含有該核酸的組合物與綴合物及製備方法和用途
CN120457205A (zh) * 2022-12-22 2025-08-08 上海舶望制药有限公司 抑制17β-羟基类固醇脱氢酶13型(HSD17B13)表达的组合物和方法
WO2024255748A1 (zh) * 2023-06-16 2024-12-19 施能康医药科技(苏州)有限公司 靶向17-β-羟基类固醇脱氢酶13的核酸及其用途
AU2024331015A1 (en) * 2023-08-30 2026-02-26 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of inhibin subunit beta e (inhbe), pharmaceutical compositions thereof, and methods of use
WO2025076225A1 (en) * 2023-10-04 2025-04-10 Enanta Pharmaceuticals, Inc. 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof
WO2025074157A1 (en) 2023-10-06 2025-04-10 Glaxosmithkline Intellectual Property (No.3) Limited Treatment of a non-alcoholic fatty liver disease
WO2026057015A1 (zh) * 2024-09-14 2026-03-19 深圳信立泰药业股份有限公司 用于抑制17β-HSD13基因表达的RNAi剂及其制备方法和用途
WO2026082165A1 (zh) * 2024-10-18 2026-04-23 正大天晴药业集团股份有限公司 修饰的双链核糖核酸
WO2026141239A1 (ja) * 2024-12-24 2026-07-02 東亞合成株式会社 Ｈｓｄ１７ｂ１３を標的とした二本鎖ｒｎａ及びその利用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US5624813A (en) 1994-04-21 1997-04-29 Mahant; Vijay K. NAD(P)+ /NAD(P)H based chemiluminescent diagnostics
AU1067697A (en) 1995-12-05 1997-06-27 Jouko Antero Oikarinen Hsd17b1 promoter, enhancer, silencer and use thereof
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US6391311B1 (en) 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
FR2801218B1 (fr) 1999-11-23 2001-12-28 Hoechst Marion Roussel Inc Compositions pharmaceutiques comprenant de la trimegestone, leurs procedes de preparation ainsi que le conditionnement primaire les renfermant
EP2305813A3 (en) 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US7754709B2 (en) 2003-06-10 2010-07-13 Solvay Pharmaceuticals Bv Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds
US20080299042A1 (en) 2004-04-30 2008-12-04 Biogen Idec Ma Inc. Membrane Associated Molecules
CA2566286A1 (en) 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
FR2904000A1 (fr) 2006-07-19 2008-01-25 Galderma Res & Dev S N C Snc Modulateurs de hsd17b7 dans le traitement de l'acne ou de l'hyperseborrhee
CN101500548A (zh) 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
WO2010028110A2 (en) 2008-09-04 2010-03-11 Board Of Regents, The University Of Texas System Sequence variations in pnpla3 associated with hepatic steatosis
PH12012501596A1 (en) 2010-02-24 2017-02-03 Arrowhead Res Corporation Compositions for targeted delivery of sirna
US9290760B2 (en) 2010-09-15 2016-03-22 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
CA2842039A1 (en) 2011-08-26 2013-03-07 Arrowhead Research Corporation Poly(vinyl ester) polymers for in vivo nucleic acid delivery
MX2014001965A (es) 2012-04-18 2014-03-31 Arrowhead Res Corp Polimeros de poli(acrilato) para suministro de acido nucleico in vivo.
WO2013177060A2 (en) 2012-05-20 2013-11-28 Trustees Of Boston University Methods and systems for monitoring, diagnosing, and treating chronic obstructive polmonary disease
US20150147761A1 (en) 2012-06-20 2015-05-28 Helmut E. Meyer Specific biomarkers for hepatocellular carcinoma (hcc)
CN103520724B (zh) * 2013-10-23 2016-05-25 江苏美迪森生物医药有限公司 Hsd17b13蛋白或其编码基因的抑制剂的新用途
EP3169776B1 (en) 2014-07-14 2025-09-03 The Regents of The University of California Crispr/cas transcriptional modulation
WO2016081444A1 (en) * 2014-11-17 2016-05-26 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
CN104698108B (zh) 2015-03-26 2016-11-09 中国药科大学 一种利用固定化酶筛选I型17β羟类固醇脱氢酶抑制剂的方法
WO2017048620A1 (en) 2015-09-14 2017-03-23 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
JOP20160211B1 (ar) * 2015-10-01 2021-08-17 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
JOP20170057B1 (ar) * 2016-03-07 2022-03-14 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة كمركبات علاجية
JOP20170056B1 (ar) 2016-09-02 2021-08-17 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة
RU2019121801A (ru) 2016-12-14 2021-01-15 Лигандал, Инк. Композиции и способы для доставки полезной нагрузки в виде нуклеиновой кислоты и/или белка
US10450565B2 (en) 2017-01-10 2019-10-22 Arrowhead Pharmaceuticals, Inc. Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
CA3049980A1 (en) * 2017-01-23 2018-07-26 Regeneron Pharmaceuticals, Inc. Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
US10533256B2 (en) 2017-10-09 2020-01-14 GKN Aerospace Transparency Systems, Inc. Hydrophobic coatings for metals incorporating anodic and rare-earth oxides and methods of applying same
AU2018348195B2 (en) 2017-10-11 2025-05-15 Regeneron Pharmaceuticals, Inc. Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
MY207352A (en) 2018-03-21 2025-02-21 Regeneron Pharma 17-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
US20210000906A1 (en) 2018-03-21 2021-01-07 Ionis Pharmaceuticals, Inc. Modulation of hsd17b13 expression
US12534728B2 (en) * 2018-09-19 2026-01-27 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of 17beta-HSD type 13 (HSD17B13), compositions thereof, and methods of use
US20240002857A1 (en) * 2022-05-09 2024-01-04 Sanegene Bio Usa Inc. Double stranded rna targeting 17-beta hydroxysteroiddehydrogenase 13 (hsd17b13) and methods of use thereof

Also Published As

Publication number Publication date
BR112021005137A2 (pt) 2021-06-15
PH12021550423A1 (en) 2021-09-20
MY209138A (en) 2025-06-24
TWI870358B (zh) 2025-01-21
TW202540423A (zh) 2025-10-16
MX2021003077A (es) 2021-05-27
AU2019342117B9 (en) 2026-06-18
JP2025186315A (ja) 2025-12-23
WO2020061177A1 (en) 2020-03-26
CL2021000669A1 (es) 2021-10-29
AU2019342117B2 (en) 2026-06-04
CN113164509A (zh) 2021-07-23
JP2024112838A (ja) 2024-08-21
CN122235140A (zh) 2026-06-19
IL281597A (en) 2021-05-31
JP7488254B2 (ja) 2024-05-21
CA3109553A1 (en) 2020-03-26
EP3852769A1 (en) 2021-07-28
US12534728B2 (en) 2026-01-27
US20220056454A1 (en) 2022-02-24
CO2021003446A2 (es) 2021-04-08
SG11202101698WA (en) 2021-04-29
TW202024324A (zh) 2020-07-01
IL281597B1 (en) 2026-05-01
PE20211212A1 (es) 2021-07-05
CN113164509B (zh) 2026-04-10
KR20210061380A (ko) 2021-05-27
JP2022501040A (ja) 2022-01-06
KR102769565B1 (ko) 2025-02-20
UY38382A (es) 2020-03-31
JP7741927B2 (ja) 2025-09-18
EP3852769A4 (en) 2023-12-13
AU2019342117A1 (en) 2021-03-04
AU2019342117A2 (en) 2021-03-11
CR20210186A (es) 2021-06-14

Similar Documents

Publication Publication Date Title
CO2021003446A2 (es) Agentes de arni para inhibir la expresión de 17beta-hsd tipo 13 (hsd17b13), composiciones de dichos agentes, y métodos de uso
CL2024003470A1 (es) Agente de iarn para inhibir la expresión de un gen de apoc3; composición; y uso.
CO2022013746A2 (es) Agentes de arni para inhibir la expresión de pnpla3, composiciones farmacéuticas de estos, y métodos de uso
MX2024003790A (es) Agentes de interferencia de acido ribonucleico (iarn) de alfa-1 antitripsina (aat), composiciones que incluyen agentes de iarn aat y metodos de uso.
CL2021001195A1 (es) Agentes de iarn para infección causada por el virus de la hepatitis b. (divisional de solicitud 201900278)
ECSP20018305A (es) Agentes de iarn y composiciones para inhibir la expresión de la angiopoyetina tipo 3 (angptl3) y métodos de uso
BR112014010223B8 (pt) uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
UY39417A (es) Agentes de arni para inhibir la expresión de dux4, composiciones de dichos agentes, y métodos de uso
CL2018000803A1 (es) Composiciones y métodos para inhibir la expresión génica de lpa.
BR112016029781A2 (pt) composições e métodos para inibir a expressão de gene de alfa-1 antitripsina
MX360827B (es) Metodos para tratar la esteatohepatitis no alcoholica (nash) usando productos de cisteamina.
BR112016024020A2 (pt) composição farmacêutica
CO2022000016A2 (es) Metodos para el tratamiento de la deficiencia de alfa-1 antitripsina (aatd)
MX2024012237A (es) Composiciones y metodos para el tratamiento de enfermedades hepaticas con moleculas de acido ribonucleico interferente peque?o (siarn) dirigidas a la proteina efectora b similar a dff45 que induce la muerte celular (cideb)
CO2020004244A2 (es) Métodos y composiciones para tratar enfermedades pulmonares crónicas
AR114739A1 (es) AGENTES DE ARNi PARA INHIBIR LA EXPRESIÓN DE 17b-HSD TIPO 13 (HSD17B13), COMPOSICIONES DE DICHOS AGENTES, Y MÉTODOS DE USO
MX2022011128A (es) Composicion farmaceutica para la prevencion o el tratamiento de la esteatohepatitis no alcoholica.
MX2020003718A (es) Composiciones y metodos para el tratamiento de fibrosis.
AR133962A1 (es) Composiciones y métodos para tratar enfermedad de hígado graso no alcohólico
AR126179A1 (es) AGENTES DE RNAi PARA INHIBIR LA EXPRESIÓN DE XANTINA DESHIDROGENASA (XDH), COMPOSICIONES FARMACÉUTICAS DE ESTOS Y MÉTODOS DE USO
EA201991675A1 (ru) СРЕДСТВА ДЛЯ РНКи АЛЬФА-1-АНТИТРИПСИНА (AAT), КОМПОЗИЦИИ, СОДЕРЖАЩИЕ СРЕДСТВА ДЛЯ РНКи AAT, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
MX391381B (es) EL USO DE 3ß-ARAQUIDILAMINO-7A,12A-DIHIDROXI-5ß-COLAN-24-OICO (ARAMCHOL) PARA INHIBIR LA FIBROSIS HEPÁTICA EN UN SUJETO QUE PADECE ENFERMEDAD DE HÍGADO GRASO.
AR113014A1 (es) AGENTES DE iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DE LA APOLIPOPROTEÍNA C-III (APOC3)